NeuraWorx Closes Oversubscribed Seed Round for Cerebrovascular Pacing System
Summary
NeuraWorx Medical Technology has closed an oversubscribed seed funding round led by Nexus NeuroTech Ventures with participation from Foothill Ventures, Verge HealthTech Fund, and Wisconsin Alumni Research Foundation. Originally developed at the University of Wisconsin-Madison, the company is developing the Cerebrovascular Pacing System, a first-in-class bioelectronic therapy targeting cerebrovascular and glymphatic dysfunction in neurodegenerative and neuropsychiatric diseases. The approach enhances brain fluid dynamics to remove waste and improve brain health.
Why it matters
NeuraWorx represents an emerging frontier in neurotechnology: targeting the brain's waste clearance system rather than direct neural stimulation or recording. Growing research links glymphatic dysfunction to Alzheimer's, Parkinson's, and other neurodegenerative diseases, making this a scientifically compelling therapeutic target. The oversubscribed round validates the approach and provides capital to build a world-class team in neuroscience, clinical development, and regulatory affairs needed to translate this novel platform into patient benefit.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial